FEATURED

“This integration represents a significant leap forward in our mission to enrich remote communication and empower developers to build real-time communication solutions with advanced AI capabilities,” said QuickBlox CEO, Nate MacLeitch.

Inify Laboratories offers specialized pathology diagnostics for prostate cancer, the second most common cancer among men in the Western world. It clearly targets present and growing challenges.

“This purchase represents an important component of our strategic manufacturing buildout,” said Dr. Tim Bertram, Chief Executive Officer of ProKidney. “With a staged investment strategy based on the clinical trial success of REACT, potential regulatory approval, and ultimately commercial demand, if approved, we intend, along with our current Winston-Salem facility, to supply enough REACT to match initial commercial demand. Subject to the outcome of the proact 1 and proact 2 clinical trials, we are targeting a Biological Licensing Agreement submission for Food and Drug Administration approval of REACT in 2026.